MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock
$4,493K
Net cash flows
provided by financing...
$4,466K
Canceled cashflow
$27K
Net increase
(decrease) in cash and cash...
$522K
Canceled cashflow
$3,944K
Payments related to
issuance of common stock
$27K
Stock-based compensation
expense
$4,725K
Accounts payable
$398K
Accrued expenses
related party
$23K
Net cash flows used
in operating...
-$3,944K
Canceled cashflow
$5,146K
Net loss
-$8,985K
Accrued expenses and
other current...
-$66K
Due to related party
-$39K
Back
Back
Cash Flow
source: myfinsight.com
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)